Version 1
: Received: 16 April 2020 / Approved: 17 April 2020 / Online: 17 April 2020 (15:15:12 CEST)
Version 2
: Received: 2 October 2020 / Approved: 5 October 2020 / Online: 5 October 2020 (11:07:50 CEST)
How to cite:
Rickli, J.M.; Pomaleski, G.; Magno Gonçalves, M.V. CANOMAD : A Multi-Faceted Disease. Preprints2020, 2020040303. https://doi.org/10.20944/preprints202004.0303.v1
Rickli, J.M.; Pomaleski, G.; Magno Gonçalves, M.V. CANOMAD : A Multi-Faceted Disease. Preprints 2020, 2020040303. https://doi.org/10.20944/preprints202004.0303.v1
Rickli, J.M.; Pomaleski, G.; Magno Gonçalves, M.V. CANOMAD : A Multi-Faceted Disease. Preprints2020, 2020040303. https://doi.org/10.20944/preprints202004.0303.v1
APA Style
Rickli, J.M., Pomaleski, G., & Magno Gonçalves, M.V. (2020). CANOMAD : A Multi-Faceted Disease. Preprints. https://doi.org/10.20944/preprints202004.0303.v1
Chicago/Turabian Style
Rickli, J.M., Gabriela Pomaleski and Marcus Vinícius Magno Gonçalves. 2020 "CANOMAD : A Multi-Faceted Disease" Preprints. https://doi.org/10.20944/preprints202004.0303.v1
Abstract
Objective: Elucidate the main clinical aspects of the CANOMAD spectrum.Methods: Bibliographical review trough databases (PubMed, Google Scholar, Orphanet, Oxford Academic) of articles from 1985 (1) to 2019 and later selection of the most applicable of the above, in order to construct a non-systematic review.Conclusion:CANOMAD is a chronic-ataxic autoimmune neuropathy associated with IgM monoclonal gammopathy. The correct diagnosis of this rare and multi-faceted disease will help optimal treatment.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.